Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Drug Therapy 43%
3. Neoplasms 37%
4. Kaposi's Sarcoma 32%
5. Neoadjuvant Therapy 29%
6. Acquired Immunodeficiency Syndrome 28%
7. Trastuzumab 26%
8. Therapeutics 26%
9. liposomal doxorubicin 22%
10. Docetaxel 22%
11. AIDS-related Kaposi sarcoma 21%
12. HIV 19%
13. Bevacizumab 18%
14. Anastrozole 17%
15. Survival 16%
16. Carboplatin 14%
17. Triple Negative Breast Neoplasms 14%
18. Irinotecan 14%
19. Paclitaxel 14%
20. Doxorubicin 13%
21. Safety 13%
22. Progression-Free Survival 13%
23. Anthracyclines 12%
24. Maximum Tolerated Dose 12%
25. Breast 12%
26. Biomarkers 11%
27. Recurrence 11%
28. palbociclib 11%
29. Radiotherapy 11%
30. Non-Small Cell Lung Carcinoma 10%
31. Estrogen Receptors 10%
32. Pharmacokinetics 10%
33. Residual Neoplasm 10%
34. Randomized Controlled Trials 10%
35. Lapatinib 10%
36. gemcitabine 9%
37. Lymphoma 9%
38. anti-IGF-1R antibody A12 9%
39. Non-Hodgkin's Lymphoma 9%
40. Heterografts 9%
41. Bortezomib 8%
42. Placebos 8%
43. Adjuvant Chemotherapy 8%
44. veliparib 8%
45. Estrogens 8%
46. Confidence Intervals 8%
47. Toll-Like Receptor 8 7%
48. HIV Infections 7%
49. MK 2206 7%